IGC Pharma (IGC) EBT Margin (2010 - 2025)
IGC Pharma's (IGC) quarterly EBT Margin came in at 953.4% in Q3 2025, down 53666.0% year-over-year from N/an in Q3 2024, and down 124.29% quarter-over-quarter from 425.08% in Q2 2025.
Powered by 
Analysis
IGC Pharma (IGC) EBT Margin (2010 - 2025) Analysis & Trends
IGC Pharma (IGC) has reported EBT Margin for 16 consecutive years, with 953.4% the latest figure, recorded in Q3 2025.
- On a quarterly basis, EBT Margin fell 53666.0% year-over-year to 953.4% in Q3 2025; TTM through Sep 2025 was 532.38%, a 53009.0% increase from a year earlier, with the FY2026 full-year figure at 757.73%, down 19746.0% from the prior year.
- EBT Margin was 953.4% for Q3 2025 at IGC Pharma, down from 425.08% in the prior quarter.
- Over five years, EBT Margin peaked at 363.03% in Q1 2025 and troughed at 7757.14% in Q3 2021.
- A 5-year average of 1843.83% and a median of 977.97% in 2024 frame the typical range for EBT Margin.
- The widest YoY moves for EBT Margin: up 723512 bps in 2021, down 643154 bps in 2021.
- Over 5 years, EBT Margin stood at 1676.76% in 2021, then jumped by 60 bps to 677.41% in 2022, then tumbled by 304 bps to 2739.71% in 2023, then surged by 74 bps to 711.67% in 2024, then sank by 34 bps to 953.4% in 2025.
- The last three EBT Margin figures came in at 953.4% (Q3 2025), 425.08% (Q2 2025), and 363.03% (Q1 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 27.53% |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -131.41% |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 41.75% |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 35.61% |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 35.78% |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -528.97% |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 13.77% |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 4.84% |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -20,427.46% |
| 10 | IGC Pharma | 27.77 Mn | 27.51 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2025 | -953.40% |
| Jun 30, 2025 | -425.08% |
| Mar 31, 2025 | -363.03% |
| Dec 31, 2024 | -711.67% |
| Sep 30, 2024 | -416.75% |
| Jun 30, 2024 | -874.26% |
| Mar 31, 2024 | -977.97% |
| Dec 31, 2023 | -2,739.71% |
| Sep 30, 2023 | -842.27% |
| Jun 30, 2023 | -373.87% |
| Mar 31, 2023 | -2,427.71% |
| Dec 31, 2022 | -677.41% |
| Sep 30, 2022 | -1,208.91% |
| Jun 30, 2022 | -1,313.68% |
| Mar 31, 2022 | -5,330.33% |
| Dec 31, 2021 | -1,676.76% |
| Sep 30, 2021 | -7,757.14% |
| Jun 30, 2021 | -2,322.08% |
| Mar 31, 2021 | -3,640.74% |
| Dec 31, 2020 | -2,150.93% |